Trial endpoints
Tumors, Prostate Cancer
TUMORS, DISEASE, PROSTATE CANCER
The primary endpoint was rPFS by blinded independent central review per Response Evaluation Criteria in Solid Tumors (version 1.1; soft tissue disease) and Prostate Cancer Clinical Trials Working Group 3 (bone disease)Exploratory subgroup analyses were conducted for rPFS by baseline characteristics (